Man Group PLC Atea Pharmaceuticals, Inc. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.17 $46,370 - $65,772	-10,660 Reduced 15.58%	57,777 $277,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $16,470 - $26,369	3,000 Added 4.58%	68,437 $389,000
Q2 2022 Aug 15, 2022	BUY	$5.33 - $8.18 $124,386 - $190,896	23,337 Added 55.43%	65,437 $465,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $197,461 - $329,939	-35,902 Reduced 46.03%	42,100 $304,000
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $73,693 - $428,420	-9,608 Reduced 10.97%	78,002 $697,000
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $1.58 Million - $2.61 Million	74,307 Added 558.57%	87,610 $3.07 Million
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $255,683 - $785,941	13,303 New	13,303 $285,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $281M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.